Lauxera Capital Partners is a venture capital firm that specializes in investing in and scaling up innovative companies in the technology and healthcare sectors. The firm leverages its extensive network and operational expertise to support entrepreneurs and drive growth.

Lauxera Capital Partners

Lauxera Capital Partners is an independent, international, healthcare-focused asset management company. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with experience across international markets, we empower European healthtech entrepreneurs to deliver the growth promised by their innovations.Lauxera was created in 2020 and has offices in Paris and San Francisco.

LAUXERA CAPITAL PARTNERS

On 8 March 2022, International Women’s Day is being celebrated under the theme “Gender equality today for a sustainable tomorrow”, recognizing the contribution of women and girls around the world who are leading the charge on climate change adaptation, mitigation, and response, to build a more sustainable future for all.

Today, LAUXERA CAPITAL PARTNERS celebrates #InternationalWomensDay and we take time to commemorate the cultural, political, and socioeconomic achievements of women; we believe that inclusion and diversity are fundamental to our success!

Collectively we can all #BreakTheBias!

#BreakTheBias #InternationalWomensDay #genderequality

We are very proud to be a new member of the iC International (iCI). 

iCI is a leading climate initiative for private equity. Members of iCI commit to recognising the risks and opportunities that climate change presents to their investments, contribute to the Paris Agreement’s objectives, and actively engage with portfolio companies to reduce their greenhouse gas emissions. 

iCI is endorsed by the UN-sponsored Principles for Responsible Investment (“PRI”), of which LAUXERA CAPITAL PARTNERS is also a signatory.

LAUXERA CAPITAL PARTNERS supports iCI's mission to address the grave threats posed by climate change. Advancing human health does not have to come at the expense of this critical priority. Improving the efficiency of today’s largely person-based care delivery paradigm with new technology can be part of the solution, along with purposeful efforts by all companies to reduce emissions and decarbonize operations.

#iCI #PRI #ClimateChange #ResponsableInvestor #ESG #sustainability

Pierre Moustial Alex Slack Samuel Levy Edoardo Fracchia Nicolas Paulmier Charles Cornevin Charlotte Fissette Ruben Cohen-Aknine Lise Bettoun Camille Compain-Tissier Alessandra Petiot Axel Gonnon Julie Jonte Elsy Boglioli Hofman Jeffrey Flier Taylor Harris Denis DELVAL Stéphane Mulard Milan Schreuer MD

Why LAUXERA CAPITAL PARTNERS? Discover the #goals and #vision of our #healthtech investment firm 🚀LAUXERA CAPITAL PARTNERS with our Founding Partner Samuel Levy.

“We are Health Technology commercial pure players; we find breakthrough technologies in Europe in Healthtech and we help them succeed commercially all over the world with a focus on the US market”.

LAUXERA CAPITAL PARTNERS is an independent, international investment firm based in Paris & San Francisco focused exclusively on healthcare #growthcompanies.

Our mission is to partner with ambitious entrepreneurs to build healthtech category champions. 

Find out more: 👉 https://lauxera.com/

More about our final closing in our press release: https://lauxera.com/news/

#growth  #privateequity  #healthtech  #investment  #innovation

Pierre Moustial Alex Slack Samuel Levy Edoardo Fracchia Nicolas Paulmier Charles Cornevin Charlotte Fissette Ruben Cohen-Aknine Lise Bettoun Camille Compain-Tissier Alessandra Petiot Axel Gonnon Julie Jonte Elsy Boglioli Hofman Jeffrey Flier Taylor Harris Denis DELVAL Stéphane Mulard Milan Schreuer MD

CB Insights has just revealed the top 150 private companies using digital technology to transform healthcare.
We are very proud to see Caresyntax in the selection, recognized as one of the 150 most promising private digital health companies in the world!
Congratulations to Dennis Kogan, Bjoern von Siemens and the entire team, who are collectively working very hard to create the surgical software platform of the future!

#surgery #medical #healthcare #caresyntax

Pierre Moustial Alex Slack Samuel Levy

Metric
Company Name	Lauxera Capital Partners
Symbol
MSH ID	COM:LAUXERA
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Venture Capital
Country	FR
Stage
Employee Count	20
Website	lauxera.com
LinkedIn	lauxera-capital-partners
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	90.47
28-Day Growth Score	17.75
90-Day Growth Score	13.37
365-Day Growth Score	12.32

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:LAUXERA

Lauxera Capital Partners

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue